Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Phase 1 Recruiting

214 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT03844256 2022-08-12

CRIMI

Phase 1/2 Recruiting

50 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT00121251 2021-04-06

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Phase 1/2 Completed

17 enrolled 13 charts

Genitourinary

Carcinoma, Renal Cell

NCT00006023 2019-06-26

Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Genitourinary

Prostatic Neoplasms

NCT02423954 2018-07-02

NivoPlus

Phase 1/2 Terminated

33 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00496587 2017-07-19

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Phase 2 Completed

34 enrolled 9 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1 Withdrawn

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT00042965 2016-07-14

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

60 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003704 2016-07-06

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Phase 1 Completed

51 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Testicular Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00124566 2016-01-18

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Phase 2 Completed

135 enrolled

Genitourinary

Prostatic Neoplasms

NCT00151047 2015-01-21

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

Phase 2 Completed

15 enrolled

Genitourinary

Prostatic Neoplasms

NCT00523640 2014-02-11

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

Phase 2 Terminated

30 enrolled 18 charts

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00058318 2012-11-02

S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer

Phase 2 Completed

43 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01182142 2010-08-24

Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Phase 2 Completed

51 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00591188 2009-05-01

Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

Phase 2 Completed

49 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00226980 2009-04-14

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Phase 2 Completed

30 enrolled

Genitourinary

Kidney Neoplasms

NCT00496301 2009-01-14

SOGUG-02-06

Phase 2 Completed

40 enrolled

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

KEYVIBE-005

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

IVY

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

SMMART Adaptive Clinical Treatment (ACT) Trial

CRIMI

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NivoPlus

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer

Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

SOGUG-02-06